Thank you, Fred. Good morning, everybody.
The Q1 report, along with the presentation that's on the screen now, is available on the Biotage website under the investor section. And then financial reports. So in Q1, as Fred has just commented, our revenues were softer than Q1 2024, primarily due to the volatility within bioprocessing or large molecules, as we've previously flagged. Astrea has only a small number of customers who have products in the commercial stage, i.e., Released in the market. Fluctuations in demand from these customers can and do have a material impact on its revenue on a quarterly basis. Therefore, it has been repeatedly said that you cannot judge bioprocessing performance on a quarterly basis. As our business grows and matures, we see more of our early-stage customers' modalities moving into late-stage development and into production and commercialization.
Our revenue concentration will ease and with it, our overall volatility.
However, this is not measured in quarters, but rather in years. While we cannot say when and how fast those modalities will move through the pipeline, we are confident that the actions we are taking now will deliver the best chances of future success.
Now our large molecules bioprocessing revenues were significantly down in Q1, as you've seen, due to lower plasmid preparation revenue in Q1 2025. We did not have any plasma revenue compared to approximately 90 million in Q1 2024.
However, our Plasmid preparation revenue grew by 3% compared to Q1 2024. We did see growth of 3% in our small molecules revenue. Additionally, we saw growth in China of 16% in the quarter after a few years of consistent heavy declines, as we've noted in the Q1 report.
We continued to see robust demand for our peptide systems, with demand outpacing manufacturing capacity, which has improved year on year. We experienced challenges in our analytical testing segment, with revenues declining by 8% year on year.
This was driven by both specific macro factors and the rationalization of one of our customer's operations. We acquired 37 new customers in Q1. In early-stage research, we are adopting a much more rigorous approach to pipeline management, classifying our customers by clinical stage to give us better visibility of future revenue streams.
Although we cannot predict when and if a customer will progress through the pipeline, the more customers we acquire and the more we partner with them in solving their problems, we increase our chances of future success. This, as Fred has always commented, is a numbers game requiring a medium-term outlook. While we are on this journey, we can still expect some significant short-term revenue volatility.
As Fred has commented, our gross margins in the quarter were actually very strong on a group level.
They were just under 63%, broadly on par with a very strong comparable Q1 2024 and up 1.1% sequentially on Q1, Q4 24. In bioprocessing, our Astrea business Q1 margins were 73.5%, up 7.87 points compared to Q1 2024 and 2.3 points sequentially. In the core quarter, one margins were 61.7%, up 5.1 points sequentially and just a small decline from a very strong comparable Q1 2024. Total operating costs in Q1 were $254 million, compared to $236 million in Q1 2024. However, when you adjust for one-off non-recurring costs, which were 22 million in Q1 versus 14 million in Q1 24, and the impact of effect translation costs, which we took an 8 million charge in Q1 versus a 5 million credit in Q1 2024.
They were much higher in Q1 2025 due to significant swings in the FX rates in March, mainly centered around the US dollar. Then our adjusted OpEx at 224 million was actually lower than Q1 2024 of 227 million. So in Q1, we delivered an adjusted EBITDA of 50 million. This was weighed down by the softness in the bioprocessing revenue to mitigate this. We have taken decisive action to streamline our bioprocessing cost base and drive further integration. The benefits of this will start to flow from Q2 this year.
In the quarter, we delivered adjusted cash flow from operations of 76 million, again down on the comparable quarter due to revenue softness.
However, we continue to deliver adjusted cash flow from operations ahead of adjusted EBITDA.
We finished the quarter with gross cash of 434 million and net cash of 182 million, on par with December 2024.
To conclude, like Fredric said, we recognize that this quarter's results are disappointing, none more so than to us.
However, we are very focused on putting in the building blocks for future growth.
Undoubtedly, we're facing challenging headwinds, which will make 2025 quite a volatile year. But we remain confident that the actions we're executing now will put us in a good position for future success. Recognizing the executional as well as the market risks that lie ahead of us, we're now open to take any questions.